Natalizumab es un anticuerpo monoclonal que actúa sobre un grupo de moléculas denominadas integrinas.
Definición de Natalizumab más completo

The newest research is showing that, caught early, PML doesn't have to be as much of a worry as it has been. "We used to think PML was always fatal, but now we are learning that it might not always be," says Kate Weiss, a spokesperson for Biogen, Inc., the makers of natalizumab.
Tysabri was withdrawn in February 2005 after two deaths because of PML . The Biogen Idec announced that no new cases of a PML (progressive multifocal leukoencephalopathy ) have been reported among patients taking Biogen Idec's multiple sclerosis drug Tysabri, since the FDA allowed it back into the market.
2010-09-09T18:16:31Z
2010-09-09T04:17:39Z
2010-09-09T01:43:18Z
2010-09-07T13:59:58Z
2010-09-07T11:56:40Z